OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)
Product name
OPDIVO
Date registered
Evaluation commenced
Decision date
Approval time
124 working days (255)
Active ingredients
nivolumab
Registration type
EOI
Indication
OPDIVO, as monotherapy, is now also indicated for the treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.